1
|
Deleplancque AS, Fricker-Hidalgo H, Pomares C, L’Ollivier C, Lemoine JP, Cimon B, Paris L, Houzé S, Villena I, Pelloux H, Villard O. Comparative performance of ISAGA IgM and ELISA assays for the diagnosis of maternal and congenital Toxoplasma infections: which technique could replace ISAGA IgM? Parasite 2024; 31:7. [PMID: 38334687 PMCID: PMC10854481 DOI: 10.1051/parasite/2024004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Accepted: 01/08/2024] [Indexed: 02/10/2024] Open
Abstract
The ISAGA immunocapture test for the detection of anti-Toxoplasma immunoglobulin M is a manual technique known for its excellent sensitivity and specificity. The purpose of this retrospective, multicenter study was to compare the performances and agreement between ISAGA and other IgM detection techniques before cessation of ISAGA production. The analytic performance of the different tests was evaluated using 1,341 serum samples from adults with positive IgM and negative IgG to Toxoplasma gondii, and 1,206 sera from neonates born to mothers with seroconversion. The agreement between the tests was evaluated on 13,506 adult and 5,795 child serum samples. The sensitivity of Toxo-ISAGA IgM® (adults 98.7%, neonates 63.1%) was similar to that of Platelia Toxo IgM® (adults 94.4%, neonates 64.6%), and significantly higher than Liaison Toxo IgM® (adults 90.6%), Architect/Alinity Toxo IgM® (adults 95.7%, neonates 48.6%), and Vidas Toxo IgM® (adults 81.8%, neonates 17.5%). However, the specificities varied between 24.4% (Platelia Toxo IgM®) and 95.2% (Liaison Toxo IgM®) in adults and were >95% for all tests in neonates. An analysis of the kappa coefficients showed better agreement between ISAGA IgM® and the other tests in children (0.75-0.83%) than in adults (0.11-0.53%). We conclude that, in the absence of Toxo-ISAGA IgM®, the association of a very sensitive technique (Platelia Toxo IgM® or Architect/Alinity Toxo IgM®) and a very specific technique (Vidas Toxo IgM® or Liaison Toxo IgM®) is recommended for IgM detection in adult sera. For neonates, Platelia Toxo IgM® appeared to be the best alternative to replace Toxo-ISAGA IgM®.
Collapse
Affiliation(s)
- Anne-Sophie Deleplancque
-
Centre National de Référence Toxoplasmose – Pôle Sérologie, Hôpitaux Universitaires de Strasbourg Strasbourg France
-
CHU Lille, Parasitology Mycology Department, INSERM U1285, CNRS UMR 8576, Glycobiology in Fungal Pathogenesis and Clinical Applications, Université de Lille Lille France
| | - Hélène Fricker-Hidalgo
-
Centre National de Référence Toxoplasmose – Pôle Sérologie, Hôpitaux Universitaires de Strasbourg Strasbourg France
-
Laboratory of Parasitology and Mycology, Grenoble Alpes University Hospital and Institute for Advanced Biosciences, Grenoble Alpes University, INSERM U1209, CNRS UMR5309 Grenoble France
| | - Christelle Pomares
-
Centre National de Référence Toxoplasmose – Pôle Sérologie, Hôpitaux Universitaires de Strasbourg Strasbourg France
-
Parasitology-Mycology laboratory, Côte d’Azur University, INSERM 1065, Nice University Hospital Nice France
-
Centre Méditerranéen de Médecine Moléculaire (C3 M), U1065, Université Côte d’Azur, INSERM, Archimed Building 151 route Saint Antoine de Ginestière Nice France
| | - Coralie L’Ollivier
-
Centre National de Référence Toxoplasmose – Pôle Sérologie, Hôpitaux Universitaires de Strasbourg Strasbourg France
-
IHU-Méditerranée Infection, Assistance Publique Hôpitaux de Marseille (AP-HM) Marseille France
-
Aix Marseille University, IRD, AP-HM, SSA, VITROME, IHU Méditerranée Marseille France
| | | | - Bernard Cimon
-
Centre National de Référence Toxoplasmose – Pôle Sérologie, Hôpitaux Universitaires de Strasbourg Strasbourg France
-
Laboratoire de Parasitologie-Mycologie, CHU d’Angers Angers France
-
Angers University, Brest University, IRF, SFR 4208 ICAT Angers France
| | - Luc Paris
-
Centre National de Référence Toxoplasmose – Pôle Sérologie, Hôpitaux Universitaires de Strasbourg Strasbourg France
-
Parasitology laboratory, AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière Paris France
| | - Sandrine Houzé
-
Centre National de Référence Toxoplasmose – Pôle Sérologie, Hôpitaux Universitaires de Strasbourg Strasbourg France
-
Parasitology laboratory, AP-HP, Hôpital Bichat - Claude Bernard Paris France
-
University of Paris Cité, IRD 261, MERIT Paris France
| | - Isabelle Villena
-
Centre National de Référence Toxoplasmose – Pôle Sérologie, Hôpitaux Universitaires de Strasbourg Strasbourg France
-
Department of Parasitology and Medical Mycology, National Reference Centre on Toxoplasmosis, Reims Hospital Reims France
-
Team EA 7510, SFR CAP-SANTE, Reims Champagne Ardenne University Reims France
| | - Hervé Pelloux
-
Centre National de Référence Toxoplasmose – Pôle Sérologie, Hôpitaux Universitaires de Strasbourg Strasbourg France
-
Laboratory of Parasitology and Mycology, Grenoble Alpes University Hospital and Institute for Advanced Biosciences, Grenoble Alpes University, INSERM U1209, CNRS UMR5309 Grenoble France
| | - Odile Villard
-
Centre National de Référence Toxoplasmose – Pôle Sérologie, Hôpitaux Universitaires de Strasbourg Strasbourg France
-
Institut de Parasitologie et de Pathologie Tropicale, UR7292 Dynamique des Interactions Hôte-Pathogène, Fédération de Médecine Transrationnelle, Université de Strasbourg Strasbourg France
-
Laboratoire de Parasitologie et Mycologie Médicale, Hôpitaux Universitaires de Strasbourg Strasbourg France
| |
Collapse
|
2
|
Guillon G, Yearwood G, Snipes C, Boschi D, Reed MR. Human anti-HIV IgM detection by the OraQuick ADVANCE® Rapid HIV 1/2 Antibody Test. PeerJ 2018; 6:e4430. [PMID: 29507828 PMCID: PMC5834934 DOI: 10.7717/peerj.4430] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Accepted: 02/09/2018] [Indexed: 01/26/2023] Open
Abstract
The Centers for Disease Control and Prevention (CDC) and many public health jurisdictions continue to advocate for the most sensitive rapid HIV test that is available. Currently, the recommendation is to utilize tests that can detect HIV infection biomarkers within 30 days of infection, when initial immune responses are mounted. The infected patient's IgM response is often used to detect acute infection within a 20-25 days window after infection. This requirement applies to lab-based testing with automated analyzers and rapid, point of care (POC) testing used for screening in a non-clinical setting. A recent study has demonstrated that POC tests using a Protein A-based detection system can detect samples with predominantly HIV-1 IgM reactivity (Moshgabadi et al., 2015). The OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test (OraQuick ADVANCE®) also uses Protein A as the detection protein in the antibody-binding colloidal gold conjugate, so it is expected that the OraQuick ADVANCE® Test will also detect samples with predominantly IgM reactivity. This report definitively demonstrates that the OraQuick ADVANCE® Test can detect IgM antibodies during an acute infection window period of approximately 20-25 days after infection, and is therefore suitable for use in testing environments requiring adherence to current CDC recommendations.
Collapse
|